2026 · 2nd Quarter (Apr 1 - June 30)

BIOMARIN PHARMACEUTICAL INC.

Filed by BIOMARIN PHARMACEUTICAL INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Amendment
Posted: Jul 20, 2026
Income: Not reported
Expenses: $340,000.00
Registrant: BIOMARIN PHARMACEUTICAL INC.
Client: BIOMARIN PHARMACEUTICAL INC.
Filing UUID: 20d88202-1b50-4f0b-98a7-b2eaff52c59a
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

MMM · Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT

TAR · Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARDE

MED · Medical/Disease Research/Clinical Labs

GENERAL DISCUSSIONS REGARDING CLINICAL TRIAL MODERNIZATION

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.